Strategic Alliance Management Congress
Strategic Alliance Management Congress Mobile
See Who Attends
14th Annual Strategic Alliance Management Congress
-第14回戦略的提携管理学会-
開催日:2017年5月1-3日
開催地:米国ペンシルバニア州フィラデルフィア、Philadelphia Marriott Downtown

Strategic Alliance Management Congress

新たな薬剤や併用療法の開発が成功裏に進むなか、企業間の提携を支えるエコシステムが重要な役割を担うようになっています。製薬会社とバイオテクノロジー企業による提携の件数は増え続けており、提携関係を管理する能力の開発は、個々の提携を成功裏に推進し、価値を最大限まで高めるための重要な要素となります。その一方で、提携管理の責任者は、年々複雑化し、多様化する提携の管理、統合やダイベストメントへの対応、企業によって異なる文化の克服、組織再編、部署の移転、提携関係の解消など、多くの課題に直面しています。こうしたなか、ライフサイクル全体を通じて生物医薬品分野での提携関係を組織的に管理する効果的な手法の必要性に促される形で新たな研究領域が形成されています。

2017年5月1日から3日まで開催されるCambridge Healthtech Institute (CHI) 主催の第14回Strategic Alliance Management Congressでは、製薬会社やバイオテクノロジー企業などで提携管理や事業開発、技術移転、ライセンス契約などの業務を統括する上級幹部や専門職が一堂に会し、講演者や他の出席者と交流を深め、経験を披露し合い、ケーススタディについて議論しながら、有効な提携関係の構築に不可欠な要素について考えます。提携管理の手法を発展させる取り組みのなかで指導的な役割を担っている専門家の戦略的な識見、有効性が裏付けられている手段や手法、ビジョンなどに触れることができるこのチャンスをどうぞお見逃しなく。

最終版のアジェンダ

5月1日(月)


8:30 am プレカンファレンスワークショップの登録手続きと朝のコーヒー

9:00 am - 12:00 pm プレカンファレンスワークショップ*

Building Self-Awareness and Flexibility in Conflict Styles:
Thomas-Kilmann Conflict Mode Instrument


提携管理の重要課題の1つは、組織内の利害関係者や提携相手との違いを効果的に解消する方法を見つけ出すことにあります。トーマス・キルマンコンフリクトモード検査スタイルの評価手法というレンズを通して、提携管理の責任者が対立状況に対処し、他者を理解するための方策について考えるこのセッションでは、対立の形態についての簡単な解説に続き、出席者を交えた討論を通じて、自分たちに課された使命を果たそうとする組織と異なる使命を持つ他の組織との対立に伴う緊張関係について検討するとともに、こうした対立を率直かつ誠実で生産的な議論の遡上に乗せていくための方策について考えます。

このセッションの出席者には、調査と評価に関するページのリンクをお送りします。学会開幕前に所定の項目にご記入いただくようお願いします。

Instructors:

Electra Hui, Senior Consultant, Vantage Partners

Michael Kalikow, Senior Consultant, Vantage Partners

*別途参加登録が必要です

12:00 pm 学会の登録手続き

1:10 議長による開会と歓迎の挨拶

Kip Harry, Senior Director, Conferences, Cambridge Healthtech Institute

製薬業界における契約と提携をめぐる環境の変化

1:15 基調講演:効果的な合意形成のための考え方と秘訣

Christoph Pittius, Ph.D., Vice President and Head, Transactions, Global Portfolio & Product Strategy Business Development, AstraZeneca AB

I will give an overview of the deal-making process encompassing identification of licensing and M&A opportunities, appropriate partner selection, deal structuring and negotiation strategies. The presentation is given from the perspectives of both the licensor and the licensee and points out pitfalls to avoid and best practices to embrace. Scientific, financial, tax, accounting, human resources as well as anti-trust considerations are outlined so that the listener gets a tool box of what to consider and pull off a successful deal that results in engaged parties embracing a trusting relationship that is ready for successful alliance management once the deal is signed.

2:00 医薬品および生命科学分野の契約に対する提携の影響

Dimitri Drone, Partner and Pharmaceutical and Life Sciences Leader, Transaction Services, PwC



提携管理の出発点−提携管理機能の導入と能力の開発

2:30 ケーススタディ:提携管理の必要性

Celine Carlet, Head, Alliance Management, Global Operations Management, Ferring International SA

According to a Deloitte study 63% of the pharma industry does not have a dedicated alliance manager. This presentation will be about the lonely journey I went on introducing Alliance Management in a mid-size company with zero knowledge on contract or partnership management. This is a real life case on building an AM function from basics to a more elaborated management of AM resources.

3:00 提携管理のための要員

Lena Frank, Executive Director, Program & Alliance Management, Oncology Business Group, Eisai Inc.

Whether you are considering hiring your first alliance manager, developing an alliance management group or looking to transform your group, there are a number of factors to consider: 1. Should alliance management be a standalone function? 2. Is there a difference between alliance management and project management? 3. What skill sets and capabilities are needed in alliance management? 4. How do you find your next alliance manager?

3:30 休憩、展示会見学

提携管理能力の強化と継続的な改善のための戦略

4:10 議長の発言

Mark Coflin, Head, Alliance Management, Corporate Planning & Program Management, Shire

4:15 空を飛びながらのエンジン組み立て:すでに動いている提携を構築する取り組みから得られた教訓

Mary Jo Struttmann, Executive Director, Alliance Management, Astellas Pharma, Inc.

4:45 企業内における提携管理のための文化と能力の構築:健全な提携関係を構築し、好ましいパートナーとなるまでの長い道のり

Angela Bylancik, Executive Director BD&L, Alliance Management, Novartis Pharmaceuticals Corporation

This presentation will discuss Novartis's internal program to establish a broader alliance management culture addressing critical aspects of creating true corporate alliance capability, generating value, and selling that value to obtain C-suite support.

5:15 多様な分野で提携関係を構築する能力の獲得

Jan Twombly, CSAP, President, The Rhythm of Business

Partnering is ubiquitous. It is happening everywhere in every function of a biopharma company. New partners often come from unexpected places. An ecosystem perspective is required to address new challenges and keep traditional alliances and collaborations on track. Explore the implications on how alliance processes must adapt and evolve - from partnering models to governance and measurement. Understand the new mindset and skillset required for alliance managers to succeed now that partnering is everywhere.

5:45 歓迎レセプション、展示会見学 (スポンサーを募集しています)

7:00 1日目終了

5月2日(火)

8:00 グループ討論とスピードネットワーキング

Grab a cup of coffee and delve deeper into some of the overarching concerns facing alliances today. These are moderated roundtables with brainstorming and interactive problem solving, allowing conference participants from diverse backgrounds to have frank discussion while exchanging ideas, experiences, and developing future collaborations around a focused topic.

新たなレベル:提携管理への介入と資格

9:25 議長の発言

Stuart Kliman, J.D., Partner, Vantage Partners

9:30 基調講演:提携が実際に失敗する理由:提携の失敗と成功に関わる主な要因

Stuart Kliman, J.D., Partner, Vantage Partners

As we all know, alliances can far too easily run off the rails - people get caught in unhelpful dynamics, get stuck in problematic "act / react" cycles, and fail to engage in productive ways. To deal with these kinds of challenges Alliance Managers need to understand the system dynamics in play and to then design interventions focused on changing those in productive and ultimately sustainable ways. In this interactive presentation we will discuss many of the most common alliance disabling dynamics, their causes and how Alliance Managers can identify and intervene in them to help their alliances meet their goals.

10:15 提携のための能力:企業の能力を開発し、包括的な提携管理体制を構築する方法

Karen Denton, Director, Alliance Management, Bayer Health Care Pharmaceuticals

This presentation will detail a recent initiative at Bayer to develop and implement an over-arching alliance management competency model and associated developmental pathways for both alliance managers and those working on alliances.

10:45 休憩、展示会見学

提携関係の解消とダイベストメントの管理

11:15 提携管理のライフサイクル:関係解消に向けた交渉

Anna Maroney, Ph.D., Vice President & Head, Alliance Management, AbbVie

By the simple nature of entering into alliances to explore new opportunities, it is not surprising that some will prove to be less fruitful than initially expected. Although strategic alliances are often viewed as a critical device for pursuing growth opportunities, survey data suggest that roughly one half of all alliance portfolios underperform. Ultimately, it is in the best interest of both parties to achieve an amicable separation. The presentation will address considerations for optimal exit planning that include communication preparation, financial negotiations, and technical wind-down schedules.

11:45 ダイベストメントの管理

Dana Hughes, Vice President & Global Head, Integration and Alliance Management, Worldwide Business Development Group, Pfizer

While acquisitions and new partnerships are the engines of growth, regular pruning of your company's portfolio can be equally as important to a healthy balance sheet and enterprise. While there are a range of options to balance your investment, we will discuss important choices specific to a divestiture process and the potential impacts of those choices for organizational burden and value realization.

12:15 pm 講演を聴きながらの昼食会 (スポンサーを募集しています) または各自で昼食

選ばれるパートナー:Sanofi、Bayer、Celgene、Shire、Boehringer Ingelheim、Bristol-Myers Squibbの新たな提携管理構想

1:40 議長の発言

Frank Grams, Ph.D., Vice President, Head, Alliance Management & Transactions, Sanofi

1:45 効果的な提携管理組織の構築に関するSanofiのケーススタディ

Frank Grams, Ph.D., Vice President, Head, Alliance Management & Transactions, Sanofi

This presentation will highlight Sanofi's internal efforts for continued organizational improvements, experiences with KPIs on the alliance portfolio, and experiences with internal training of Alliance Management.

2:15 Bayerの提携管理構想

Michael Kennedy, Ph.D., MBA, Director, Alliance Management, Business Development & Licensing, Bayer HealthCare

This presentation will look at a variety of different methodologies for assessing alliance capability and then a framework for looking at different areas of that capability: Strategic - Extent to which the company is oriented for partnering success; Operational - Extent to which the capabilities and processes to support effective joint alliance execution; and Mindset/Culture - Extent to which leadership and incentives ensure the appropriate behaviors. An implementation plan for improvement will be discussed with practical examples for building on strengths and managing weaknesses.

2:45 多様な関係に対応する能力の構築

Winston Kung, Vice President, Business Development & Global Alliances, Celgene Corporation

This presentation will provide an overview of Celgene's story, including details on its driving culture, core focus and pipeline. I will also discuss how we build and manage diverse partnerships, our approach to alliance management, as well as share what's next for Celgene's partnerships.

3:15 休憩、展示会見学

4:00 提携をリードする企業の新たな能力の形成

Mark Coflin, Head, Alliance Management, Corporate Planning & Program Management, Shire

Shaping a new company with an innovative approach to Alliance Management leadership is an exciting opportunity! Shire is the leading rare disease-focused biotech focused on rare disease targeting highly specialized conditions. This presentation will discuss key learnings on designing and building the organizational Alliance Management capability, championing change and overcoming obstacles in the journey. This presentation will share the vision of success, the roadmap, and practical tips for everyone.

4:30 Boehringer Ingelheimにおける提携管理

Mark Ralph, Global Head, Contracts and Alliance Management, Boehringer Ingelheim

5:00 基調講演:機動的なアライアンスポートフォリオでの提携管理に必要なリソースの導入

Nancy Forrest, Vice President, Global Alliances and Operations, Bristol-Myers Squibb

As companies become more reliant on partnering, alliance portfolio management increases in importance. The portfolio can vary from early stage to late stage assets, 'easy' to 'complex,' and specialty to primary care. Each carries its own unique challenges, but also alliance portfolio challenges as well. In addition, new alliance models, such as clinical collaborations, are emerging, furthering complexity. This session discusses concepts of alliance portfolio management.

5:45 2日目終了

5月3日(水)

8:00 am 朝のコーヒー

現在進行中の提携関係と提携管理のケーススタディ

8:25 議長による開会の挨拶

Harry Atkins, Senior Director, Business Development & Alliance Management, Aralez Pharmaceuticals Inc.

8:30 ケーススタディの共同発表:AstraZenecaとAralezの新たな提携

Harry Atkins, Senior Director, Business Development & Alliance Management, Aralez Pharmaceuticals Inc.

Bill Dwyer, Senior Director, US Alliance Management, AstraZeneca

This co-presentation will provide a case study on a recent alliance between AstraZeneca and Aralez for the rights to branded and authorized generic Toprol-XL in the US. Alliance management and transition activities currently ongoing between AstraZeneca and Aralez Pharmaceuticals will be presented by both alliance managers.

9:15ケーススタディの共同発表:10年以上にわたって続く生物医薬品研究分野での有効な提携関係

Doug Williams, Director, Licensing & Business Development, Alliance Management, Purdue Pharma

Izumi Kawabata, Head, Alliance Management, Alliance Management and Business Development, Shionogi & Co., Ltd.

This co-presentation will provide a case study on a successful biopharma research collaboration that was initiated in 2005 between Purdue Pharma and Shionogi and still continues today. The presentation will include an overview of each company, the rationale for the alliance and the ongoing projects related to this collaboration.

10:00 休憩、展示会見学

10:30 ケーススタディ:AstraZenecaとLillyのアルツハイマー治療薬の共同開発と商業化を目的とした提携

Joseph McCullough, Ph.D., Alliance Director, AstraZeneca

In 2014, AstraZeneca and Eli Lilly and Company entered into an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease. In this presentation, I will highlight the execution of management to date, as well as discuss challenges encountered.

11:00ケーススタディ:提携管理に対する戦略的なアプローチを用いた組織の価値創造

MaryAnne McCarthy, Executive Director Alliance Management, Incyte Corporation

Over the past year we have focused on the strategic role of Alliance Management in our organization; specifically, how to create value for your organization with a strategic approach to managing partnerships. During this presentation I will discuss strategic value creation by reducing redundancy, maximizing individual contributions and modeling the future state of the alliance.

開発と製造に関する提携の改善

11:30 提携と協力に対するSandozのアプローチ

Mahen Gundecha, Head, Alliance Management, Sandoz

Sandoz is currently engaged in biotech cooperation with a number of leading organizations and continuously looks to extend its number of partnerships in the future. This strong experience combined with a successful track record of accomplishments and state-of-the-art plants, offers a unique opportunity to partners interested in pursuing manufacturing cooperation. This presentation will detail our approach to alliance management, and insights into how to get the most of a manufacturing partnership.

12:00 pm 開発と製造に関する提携の改善

Jose Ochoa, Chief Business Officer & Head, Animal Health Americas, IDT Biologika Corporation

IDT Biologika offers customers access to highly integrated development and manufacturing services, including one of the most comprehensive quality control and testing programs in the industry. This presentation will highlight the execution and lessons learned from recent alliances IDT Biologika has entered into to provide an end-to-end solution for the manufacture of antibody drug conjugates and live virus filling and finishing services.

12:30 学会閉幕




* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English

カタログ(PDF)


Premier Sponsor

 Vantage Partners 

Corporate Sponsors

  PWC

Rhythm of Business Grayscale


イベントカレンダー
医薬品関連の国際会議
メール配信サービス
メール配信サービス